Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Return on Sales (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Return on Sales for 16 consecutive years, with 0.19% as the latest value for Q1 2026.

  • For Q1 2026, Return on Sales fell 32.0% year-over-year to 0.19%; the TTM value through Mar 2026 reached 0.06%, down 13.0%, while the annual FY2025 figure was 0.13%, 8.0% down from the prior year.
  • Return on Sales hit 0.19% in Q1 2026 for Corcept Therapeutics, down from 0.12% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.34% in Q3 2022 and bottomed at 0.19% in Q1 2026.
  • Average Return on Sales over 5 years is 0.18%, with a median of 0.19% recorded in 2024.
  • Year-over-year, Return on Sales rose 7bps in 2023 and then crashed -32bps in 2026.
  • Corcept Therapeutics' Return on Sales stood at 0.16% in 2022, then soared by 44bps to 0.23% in 2023, then dropped by -27bps to 0.17% in 2024, then fell by -29bps to 0.12% in 2025, then tumbled by -260bps to 0.19% in 2026.
  • According to Business Quant data, Return on Sales over the past three periods came in at 0.19%, 0.12%, and 0.09% for Q1 2026, Q4 2025, and Q3 2025 respectively.